Quebec City-based drug developer Aeterna Zentaris Inc. and U.S. partner Keryx Biopharmaceuticals confirmed that U.S. regulators have granted fast-track approval for perifosine (KRX-0401), an oral treatment for colorectal cancer. The full US approval and market launch wouldn’t be until 2012, with the next two years spent in Phase III clinical trials. Perifosine already has “orphan drug” status in Europe and the USA for the treatment of blood cancer.